RESEARCH TRIANGLE PARK, N.C. & DANBURY, Conn.–(BUSINESS WIRE)– Quintiles en IMS Health hebben een mondiale strategische alliantie gesloten ter bevordering manier waarop biofarmaceuten bewijs uit de praktijk (real world evidence, RWE) vergaren en belangrijke inzichten toepassen op klinisch onderzoek in de laatste fase. De vandaag aangekondigde samenwerking, die elkaar aanvullende capaciteiten in RWE, operationele uitvoering, analysemiddelen en wetenschappelijke en therapeutische expertise bijeenbrengt, versnelt de beoordeling van de impact die een behandeling heeft en helpt patiënten aan betere resultaten.
Bewijs dat een medicijn effectief en veilig is in een realistische context, blijft een cruciaal onderdeel van geneesmiddelenontwikkeling. Het verbond van Quintiles en IMS Health verenigt leiders in prospectief en retrospectief onderzoek, uitvoering van onderzoek, gepatenteerde RWE-technologie en epidemiologische expertise, waarmee de bedrijven klanten een volledig overzicht geven van de impact van een therapie en de beleving van een patiënt.
Quintiles and IMS Health Announce Global Collaboration to Advance the Use of Next-Generation Real-World Evidence in Late-Stage Clinical Research
RESEARCH TRIANGLE PARK, N.C. & DANBURY, Conn.–(BUSINESS WIRE)– Quintiles and IMS Health today announced a global strategic alliance that will advance the way biopharmaceutical companies generate real-world evidence (RWE) and apply critical insights to drive late-stage clinical research. With complementary strengths in real-world data management, operational delivery, advanced analytics, and scientific and therapeutic expertise, the collaboration will accelerate assessments of treatment impact and help improve patient outcomes.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151022005287/en/
As healthcare stakeholders increase their focus on value, evidence of a medicine’s effectiveness and safety in real-world settings continues to be a critical component of drug development and healthcare delivery. This alliance brings together market-leading capabilities in prospective and retrospective research, operational study delivery, proprietary RWE technologies and epidemiological expertise to provide customers with a complete view of a product’s impact and the patient experience in clinical practice.
“As demand increases for real-world evidence, biopharmaceutical companies need to integrate data from multiple sources to accelerate critical insights for stakeholders,” said Scott Evangelista, president, Integrated Healthcare Services at Quintiles. “This collaboration greatly enhances access to healthcare data from across the world – providing customers with the critical information and the related services needed to demonstrate the value of their medicines to physicians, payers and patients.”
The alliance will combine IMS Health’s strength in technology-enabled RWE information management, deep understanding of global health systems and advanced clinical and commercial analytics with Quintiles’ global breadth of operational expertise, experience in prospective studies and scientific knowledge to support all aspects of real-world and late-phase research.
Healthcare stakeholders will benefit from IMS Health’s access to 500+ million anonymous patient records, as well as its scalable Evidence 360 RWE platform. Quintiles is providing experience in real-world and late-phase programs involving more than 74,000 sites and more than 650,000 enrolled patients in more than 100 countries since 2011 along with its award-winning Quintiles Infosario ® platform. Applying these combined strengths will enable biopharmaceutical companies to optimize physician and patient recruitment, streamline data collection and study execution, as well as improve the quality and impact of real-world evidence worldwide.
“We are excited to offer an improved method for generating healthcare evidence that addresses a long-standing need for more robust information, greater insight on disease and treatment impact, and more cost-effective data collection,” said Jon Resnick, vice president and general manager, Real-World Evidence Solutions at IMS Health. “Through this collaboration, we will help improve the body of information healthcare stakeholders can access and use – informing better decisions that benefit patients and the entire health delivery system.”
Quintiles (NYSE:Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
About IMS Health
IMS Health (NYSE:IMS) is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,500 services experts connect configurable SaaS applications to 10+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Quintiles Media Relations
Phil Bridges, +1-919-998-1653
orQuintiles Investor Relations
Todd Kasper, +1-919-998-2590
IMS Health Media Relations
Tor Constantino, +1-484-567-6732
IMS Health Investor Relations
Tom Kinsley, +1-203-448-4691